Association between albumin and recompensation in patients with hepatitis B/C virus-related decompensated liver cirrhosis

Danqing XU; Yingyuan ZHANG; Jingru SHANG; Caifen SA; Wenyan LI; Li LIU; Zhijian DONG

doi:10.12449/JCH251119

Volume 41 Issue 11

Nov. 2025

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(11): 2323-2328

PDF( 767 KB)

Association between albumin and recompensation in patients with hepatitis B/C virus-related decompensated liver cirrhosis

DOI: 10.12449/JCH251119

Yunnan Provincial Clinical Medical Center for Infectious Diseases，The Third People’s Hospital of Kunming，Kunming 650054，China

Research funding:

Science and Technology Plan Fund of Yunnan Province (2017FH001-088);

Kunming Science and Technology Plan Project (2024-1-NS-0035);

Kunming Health Science Research Project (2025-03-08-002)

More Information

Corresponding author: LIU Li， liuli197210@163.com （ORCID： 0000-0001-7712-4931）; DONG Zhijian， 13529230846@163.com （ORCID： 0009-0003-0492-2598）
Received Date: 2025-04-07
Accepted Date: 2025-06-04
Published Date: 2025-11-25

Abstract

Abstract

Objective To investigate the association between albumin （Alb） and recompensation by comparing recompensation rate between hepatitis B/C virus-related decompensated liver cirrhosis patients with different Alb levels， and to provide guidance for the identification and management of high-risk patients in clinical practice. Methods Related clinical data were collected from 734 patients with hepatitis B/C virus-related decompensated liver cirrhosis who attended The Third People’s Hospital of Kunming from January 1， 2016 to December 31， 2022， and they were divided into three groups based on the level of Alb. The linear regression analysis and chi-square test were used for trend tests. The Kaplan-Meier curve was plotted for the cumulative incidence rate of recompensation in the three groups， and the log-rank test was used for comparison between groups. A Cox proportional-hazards regression model analysis was used to investigate the association between Alb and recompensation in patients with hepatitis B/C virus-related decompensated liver cirrhosis. Results Among the 734 patients with hepatitis B/C virus-related decompensated liver cirrhosis， 270 achieved recompensation， with a recompensation rate of 36.8%. All patients had a median Alb level of 29.90 （25.90 — 34.80） g/L on admission， and according to the level of Alb， they were divided into <25.9 g/L group with 177 patients， 25.9 — 34.8 g/L group with 377 patients， and >34.8 g/L group with 180 patients； 36 patients （20.3%） in the <25.9 g/L group， 138 （36.6%） in the 25.9 — 34.8 g/L group， and 96 （53.3%） in the >34.8 g/L group achieved recompensation， and the recompensation rate increased with the increase in Alb level （χ²=41.730， P<0.001）. After adjustment for all confounding factors， compared with the <25.9 g/L group， there was a significant increase in the incidence rate of recompensation in the 25.9 — 34.8 g/L group （hazard ratio ［HR］=1.842， 95% confidence interval ［CI］： 1.274 — 2.663） and the >34.8 g/L group （HR=2.336， 95% CI： 1.575 — 3.463）. The Kaplan-Meier survival analysis showed that there was a significant difference in the cumulative incidence rate of recompensation between the three groups （χ² =41.632， P<0.001）. Conclusion Alb level is an influencing factor for recompensation in patients with hepatitis B/C virus-related decompensated liver cirrhosis， and the recompensation rate increases with the increase in Alb level.
- Hepatitis B,
- Hepatitis C,
- Liver Cirrhosis,
- Serum Albumin,
- Recompensation

FullText(HTML)

References(28)

References

[1]	Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on clinical diagnosis and therapy of liver cirrhosis[J]. Chin J Digest, 2023, 43( 4): 227- 247. DOI: 10.3760/cma.j.cn311367-2023022800093. 中华医学会消化病学分会. 中国肝硬化临床诊治共识意见[J]. 中华消化杂志, 2023, 43( 4): 227- 247. DOI: 10.3760/cma.j.cn311367-20230228-00093.
[2]	de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76( 4): 959- 974. DOI: 10.1016/j.jhep.2021.12.022.
[3]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of ascites in cirrhosis(2023 version)[J]. Chin J Hepatol, 2023, 31( 8): 813- 826. DOI: 10.3760/cma.j.cn501113-20230719-00011. 中华医学会肝病学分会. 肝硬化腹水诊疗指南(2023年版)[J]. 中华肝脏病杂志, 2023, 31( 8): 813- 826. DOI: 10.3760/cma.j.cn501113-20230719-00011.
[4]	BONACCI M, LONDOÑO MC, ESFORZADO N, et al. Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV-decompensated cirrhosis: Viral eradication and removal from the liver transplant waiting list[J]. Transpl Int, 2015, 28( 11): 1345- 1349. DOI: 10.1111/tri.12622.
[5]	RUIZ I, FERAY C, PAWLOTSKY JM, et al. Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment[J]. Liver Transpl, 2015, 21( 3): 408- 409. DOI: 10.1002/lt.24051.
[6]	BELLI LS, BERENGUER M, CORTESI PA, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study[J]. J Hepatol, 2016, 65( 3): 524- 531. DOI: 10.1016/j.jhep.2016.05.010.
[7]	WANG Q, ZHAO H, DENG Y, et al. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis[J]. J Hepatol, 2022, 77( 6): 1564- 1572. DOI: 10.1016/j.jhep.2022.07.037.
[8]	DENG Y, KANG HY, XIANG HL, et al. Durability and on-treatment predictors of recompensation in entecavir-treated patients with hepatitis B and decompensated cirrhosis[J]. JHEP Rep, 2024, 6( 7): 101091. DOI: 10.1016/j.jhepr.2024.101091.
[9]	RUAN JJ, WEN SF, WANG X, et al. Influencing factors for recompensation in patients with first-time decompensated hepatitis B cirrhosis[J]. J Clin Hepatol, 2022, 38( 8): 1796- 1800. DOI: 10.3969/j.issn.1001-5256.2022.08.015. 阮佳佳, 温世飞, 王霞, 等. 首次失代偿期乙型肝炎肝硬化患者获得再代偿的影响因素分析[J]. 临床肝胆病杂志, 2022, 38( 8): 1796- 1800. DOI: 10.3969/j.issn.1001-5256.2022.08.015.
[10]	European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J]. J Hepatol, 2010, 53( 3): 397- 417. DOI: 10.1016/j.jhep.2010.05.004.
[11]	D’AMICO G, GARCIA-TSAO G, PAGLIARO L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies[J]. J Hepatol, 2006, 44( 1): 217- 231. DOI: 10.1016/j.jhep.2005.10.013.
[12]	HOFER BS, SIMBRUNNER B, HARTL L, et al. Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis[J]. Liver Int, 2023, 43( 10): 2220- 2231. DOI: 10.1111/liv.15676.
[13]	WEN SF, RUAN JJ, SHEN JM, et al. Development and validation of a nomogram to predict recompensation in HBV-related cirrhosis with ascites as the single first decompensating event[J]. Scand J Gastroenterol, 2023, 58( 8): 915- 922. DOI: 10.1080/00365521.2023.2181037.
[14]	JALAN R, BERNARDI M. Effective albumin concentration and cirrhosis mortality: From concept to reality[J]. J Hepatol, 2013, 59( 5): 918- 920. DOI: 10.1016/j.jhep.2013.08.001.
[15]	RABBANI G, AHN SN. Structure, enzymatic activities, glycation and therapeutic potential of human serum albumin: A natural cargo[J]. Int J Biol Macromol, 2019, 123: 979- 990. DOI: 10.1016/j.ijbiomac.2018.11.053.
[16]	CASULLERAS M, FLORES-COSTA R, DURAN-GÜELL M, et al. Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis[J]. Sci Transl Med, 2020, 12( 566): eaax5135. DOI: 10.1126/scitranslmed.aax5135.
[17]	CARACENI P, O’BRIEN A, GINES P. Long-term albumin treatment in patients with cirrhosis and ascites[J]. J Hepatol, 2022, 76( 6): 1306- 1317. DOI: 10.1016/j.jhep.2022.03.005.
[18]	BAI ZH, MÉNDEZ-SÁNCHEZ N, ROMEIRO FG, et al. Use of albumin infusion for cirrhosis-related complications: An international position statement[J]. JHEP Rep, 2023, 5( 8): 100785. DOI: 10.1016/j.jhepr.2023.100785.
[19]	GINÈS P, KRAG A, ABRALDES JG, et al. Liver cirrhosis[J]. Lancet, 2021, 398( 10308): 1359- 1376. DOI: 10.1016/S0140-6736(21)01374-X.
[20]	GIANNELLI V, ROUX O, LAOUÉNAN C, et al. Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation[J]. J Hepatol, 2020, 72( 3): 463- 471. DOI: 10.1016/j.jhep.2019.10.002.
[21]	CARACENI P, RIGGIO O, ANGELI P, et al. Long-term albumin administration in decompensated cirrhosis(ANSWER): An open-label randomised trial[J]. Lancet, 2018, 391( 10138): 2417- 2429. DOI: 10.1016/S0140-6736(18)30840-7.
[22]	ZHAO HN, CHEN JH, BAI ZH, et al. Effect of human albumin on oxidative stress in patient with hepatic encephalopathy due to liver cirrhosis[J]. Clin J Med Off, 2024, 52( 9): 965- 967. DOI: 10.16680/j.1671-3826.2024.09.24. 赵浩南, 陈纪宏, 白朝辉, 等. 人血白蛋白对肝硬化肝性脑病患者氧化应激反应影响[J]. 临床军医杂志, 2024, 52( 9): 965- 967. DOI: 10.16680/j.1671-3826.2024.09.24.
[23]	BAI ZH, WANG L, LIN HY, et al. Use of human albumin administration for the prevention and treatment of hyponatremia in patients with liver cirrhosis: A systematic review and meta-analysis[J]. J Clin Med, 2022, 11( 19): 5928. DOI: 10.3390/jcm11195928.
[24]	LEACHE L, GUTIÉRREZ-VALENCIA M, SAIZ LC, et al. Meta-analysis: Efficacy and safety of albumin in the prevention and treatment of complications in patients with cirrhosis[J]. Aliment Pharmacol Ther, 2023, 57( 6): 620- 634. DOI: 10.1111/apt.17344.
[25]	ZHANG CX, CAO ZJ, XIANG XG, et al. Advances in decompensated cirrhosis treatment by human serum albumin[J]. J Shanghai Jiao Tong Univ Med Sci, 2023, 43( 1): 95- 100. DOI: 10.3969/j.issn.1674-8115.2023.01.012. 张宸溪, 曹竹君, 项晓刚, 等. 人血清白蛋白治疗失代偿期肝硬化的研究进展[J]. 上海交通大学学报(医学版), 2023, 43( 1): 95- 100. DOI: 10.3969/j.issn.1674-8115.2023.01.012.
[26]	SORT P, NAVASA M, ARROYO V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis[J]. N Engl J Med, 1999, 341( 6): 403- 409. DOI: 10.1056/NEJM199908053410603.
[27]	SIMÓN-TALERO M, GARCÍA-MARTÍNEZ R, TORRENS M, et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: A randomized double-blind study[J]. J Hepatol, 2013, 59( 6): 1184- 1192. DOI: 10.1016/j.jhep.2013.07.020.
[28]	WANG JY, ZHANG JM. Role of human blood albumin in the reversal of decompensation to decompensation in liver cirrhosis[J]. Chin Hepatol, 2024, 29( 12): 1565- 1568. DOI: 10.3969/j.issn.1008-1704.2024.12.032. 王瑾瑜, 张继明. 人血白蛋白在肝硬化失代偿逆转到再代偿中的作用[J]. 肝脏, 2024, 29( 12): 1565- 1568. DOI: 10.3969/j.issn.1008-1704.2024.12.032.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (5) PDF downloads(5)

Association between albumin and recompensation in patients with hepatitis B/C virus-related decompensated liver cirrhosis

DOI: 10.12449/JCH251119

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content